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Malaria-causing Plasmodium sporozoites are deposited in the der-
mis by the bite of an infected mosquito and move by gliding mo-
tility to the liver where they invade and develop within host
hepatocytes. Although extracellular interactions between Plasmo-
dium sporozoite ligands and host receptors provide important
guidance cues for productive infection and are good vaccine tar-
gets, these interactions remain largely uncharacterized. Thrombo-
spondin-related anonymous protein (TRAP) is a parasite cell
surface ligand that is essential for both gliding motility and inva-
sion because it couples the extracellular binding of host receptors
to the parasite cytoplasmic actinomyosin motor; however, the mo-
lecular nature of the host TRAP receptors is poorly defined. Here,
we use a systematic extracellular protein interaction screening
approach to identify the integrin αvβ3 as a directly interacting
host receptor for Plasmodium falciparum TRAP. Biochemical char-
acterization of the interaction suggests a two-site binding model,
requiring contributions from both the von Willebrand factor A
domain and the RGD motif of TRAP for integrin binding. We show
that TRAP binding to cells is promoted in the presence of integrin-
activating proadhesive Mn2+ ions, and that cells genetically tar-
geted so that they lack cell surface expression of the integrin αv-
subunit are no longer able to bind TRAP. P. falciparum sporozoites
moved with greater speed in the dermis of Itgb3-deficient mice,
suggesting that the interaction has a role in sporozoite migration.
The identification of the integrin αvβ3 as the host receptor for
TRAP provides an important demonstration of a sporozoite surface
ligand that directly interacts with host receptors.
malaria | Plasmodium falciparum | TRAP | sporozoite | integrin
Malaria is an infectious tropical disease caused by parasitesbelonging to the genus Plasmodium and is responsible for
almost half a million deaths annually (1). Infections are initiated
when an anopheline mosquito takes a blood meal and deposits
the sporozoite form of the parasite within the dermis. Sporozo-
ites are independently motile and disperse from the site of in-
oculation, enter the circulation, and invade and develop within
the liver to continue their life cycle (2). The sporozoite stage is
considered an attractive target for vaccines because this stage of
the infection is asymptomatic and extracellular sporozoites,
which are few in number, are directly exposed to host antibodies.
Plasmodium parasites move by gliding motility, a form of
movement which requires anchorage on an extracellular sub-
strate and is characterized by a lack of any locomotory organelles
and no overt change in cell shape (3). The molecular machinery
that is responsible for this gliding behavior involves a protein
complex that couples a force-generating cytoplasmic actin-
myosin motor to a membrane-spanning “invasin” belonging to
the thrombospondin-related anonymous protein (TRAP) family
whose interactions with extracellular ligands provide the neces-
sary traction to power movement and invasion (4). Plasmodium
genomes encode several different members of the TRAP family
that are largely expressed in a stage-specific manner (5), and
TRAP itself is expressed by sporozoites. TRAP is considered a
high-priority subunit malaria vaccine candidate because it is ex-
posed at the sporozoite surface and because genetic deletion of
trap in Plasmodium berghei showed it is essential for motility and
invasion (6). A virally vectored TRAP-based vaccine is able to
mediate protective effects in both animal infection models and
humans (7), making a more-detailed understanding of TRAP
function a research priority to improve these vaccines and ex-
pand our basic knowledge of parasite motility and invasion.
TRAP is a typical type I cell surface protein containing both a
von Willebrand factor A (VWA) and a thrombospondin type
1 repeat (TSR) domain. VWA and TSR domains are found in
mammalian proteins such as integrins and complement factors,
where they bind extracellular ligands, suggesting a similar role in
TRAP. This is supported by genetic studies showing that muta-
tion of the VWA and TSR domains does not affect sporozoite
motility but significantly impairs host cell invasion (8) by the
presence of an integrin-like metal ion-dependent adhesion site
(MIDAS) in the TRAP ectodomain (8), and by the binding of
recombinant proteins corresponding to the TRAP extracellular
region to human hepatocyte-derived cell lines (9, 10). Structural
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studies have suggested that extracellular binding events may
trigger a conformational change in the tandem VWA and TSR
domains which open into an elongated shape, providing the force
for parasite motility (11), and may provide an explanation for the
“stick and slip” movement of sporozoites (12).
An important question is the identity of the extracellular
molecules displayed on host cells that can interact with TRAP
and how these interactions are involved in the pathogenesis of
malaria. Previous work has suggested that TRAP interacts with
sulfated glycoconjugates (9), but the significance of this is not
clear (10). Identifying extracellular interactions between cell
surface receptor proteins can be challenging due to the diffi-
culties in solubilizing membrane-embedded proteins in their
native conformation and the often transient nature of their in-
teractions (13). We have developed approaches to express the
ectodomains of receptor proteins from Plasmodium falciparum in
a functionally active form (14) and used them in a protein in-
teraction assay called AVEXIS (avidity-based extracellular in-
teraction screen) (15) that circumvents some of these challenges.
Here, we show how we have used this approach to identify the
human integrin αvβ3 as a host receptor for P. falciparum TRAP.
Results
P. falciparum TRAP Expressed in HEK293 Cells Binds HepG2 Cells
Independently of Cell Surface Sulfates. To identify human host re-
ceptors for P. falciparum TRAP, we expressed the entire ectodo-
main as a soluble recombinant protein in mammalian cells.
Because interactions between cell surface receptor proteins are
typically weak, we purposefully oligomerized monomeric TRAP
around a streptavidin–phycoerythrin conjugate to form a fluores-
cent highly avid binding probe which stained the surface of human
HepG2 cells (Fig. 1A). To determine if this cell binding was due to
cell surface sulfated glycoconjugates, we tested whether the TRAP
ectodomain could interact with heparin, chondroitin sulfate A, or
heparan sulfate using a sensitive surface plasmon resonance assay.
Even at high concentrations of these glycoconjugates, we observed
no detectable binding with TRAP immobilized on the sensor chip
(Fig. 1B). Consistent with this, preincubating the TRAP binding
probe with these molecules before testing binding to HepG2 cells
did not affect TRAP binding activity (Fig. 1C). Lastly, we used
CRISPR/Cas9 technology to genetically ablate in HepG2 cells the
SLC35B2 gene, which encodes a transporter for 3′-phosphoade-
nosine-5′-phosphosulfate into the lumen of the Golgi apparatus
where sulfotransferases use it as a universal donor for the sulfation
Fig. 1. Recombinant P. falciparum TRAP binds HepG2 cell surfaces independently
of sulfated glycoconjugates. (A) A highly avid fluorescent P. falciparum TRAP
binding reagent stained the surface of HepG2 cells. Monomeric biotinylated TRAP
ectodomain was clustered around a streptavidin–phycoerythrin (PE) conjugate and
bound HepG2 cells, relative to a Cd200 negative control. (B) TRAP did not interact
with sulfated glycoconjugates in surface plasmon resonance assays. Heparin,
chondroitin sulfate, and heparan sulfate were injected at 1 mg/mL for 60 s over
biotinylated TRAP immobilized on a streptavidin-coated sensor chip, with no ob-
servable binding. (C) TRAP binding to HepG2 cells is unaffected by an excess of
sulfated glycoconjugates. The binding of TRAP to HepG2 cells was unaffected
when preincubated with 250 μg/mL heparin, 250 μg/mL chondroitin sulfate, or
100 μg/mL heparan sulfate. (D) TRAP binds HepG2 cells independently of cell
surface sulfated glycans. HepG2 cells in which the SLC35B2 gene had been
targeted using CRISPR/Cas9 technology retained TRAP binding. Negative controls
in A, B, and D show that Cd200 protein, expressed and oligomerized in the same
way as TRAP, does not bind HepG2 cells. −ve, negative.
Fig. 2. Integrin αvβ3 is a human receptor for P. fal-
ciparum TRAP. (A) P. falciparum TRAP ectodomain
expressed as a prey was tested for binding using the
AVEXIS assay against a library of 65 human receptor
ectodomains from the indicated architectural classes;
bait numbers correspond to named proteins in SI
Appendix, Table S1. Bars represent mean ± SD, n = 2.
(B) Biotinylated integrin αvβ3 was clustered around
streptavidin-alkaline phosphatase to create an
avid binding reagent and was captured by an
immobilized monomeric TRAP (black circles), but
not control Cd200 (blue squares). Biotinylated Cd200
similarly clustered around streptavidin-alkaline phos-
phatase did not interact with immobilized TRAP
(purple triangles). Data points represent mean ± SD,
n = 3. Data shown are representative of at least three
independent experiments. (C) Kinetic analysis showed
that TRAP and integrin αvβ3 directly interact. In-
creasing concentrations of purified TRAP ectodomain
were injected at a high flow rate (100 μL min−1) for
a contact time of 20 s over biotinylated integrin αvβ3
immobilized on a streptavidin-coated chip; binding was
quantified relative to a reference flow cell.
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of glycocalyx components, including heparan sulfate. We dem-
onstrated that TRAP binding to SLC35B2-targeted cells was
largely unaffected (Fig. 1D), even though we could show that a
significant population of these cells had lost FGFRL1 binding, a
known heparan sulfate binding protein (SI Appendix, Fig. S1).
These data demonstrate that recombinant TRAP expressed in
mammalian cells interacted with a cell surface receptor expressed
on HepG2 cells distinct from cell surface sulfated glycans.
The Integrin αvβ3 Is a Human Receptor for P. falciparum TRAP. To
determine the molecular identity of the TRAP receptor on
HepG2 cells, we selected a panel of 65 proteins from an existing
library of human cell surface receptor ectodomains available in the
laboratory (16) that were expressed on HepG2 cells (17) (SI Ap-
pendix, Table S1). This array of human receptors was probed for
direct interactions with TRAP using the AVEXIS assay, and a
clear interaction with integrin αvβ3 was immediately observed
(Fig. 2A). Integrins are a family of cell surface receptors consisting
of a complex of two noncovalently associated polypeptide chains
whose extracellular regions can exist in different ligand affinity
states formed by conformational changes induced by intracellular
or extracellular signaling events (18). We demonstrated that this
interaction was independent of the “bait–prey” orientation by
clustering the biotinylated αvβ3 integrin around a streptavidin-
alkaline phosphatase conjugate and showing that it interacted
robustly with TRAP, but not with a control bait (Fig. 2B). We next
demonstrated that TRAP and αvβ3 interacted directly using sur-
face plasmon resonance, by injecting serial dilutions of purified
TRAP over a surface containing immobilized integrin αvβ3. Ki-
netic analysis showed that the two proteins interacted directly,
from which association and dissociation rate constants of 2.95 ±
0.02 × 105 M−1·s−1 and 0.00332 ± 0.00002 s−1, were calculated
corresponding to an interaction half-life of over 3 min (Fig. 2C).
This binding affinity was unexpectedly high for an extracellular
receptor–ligand interaction, which often have half-lives in the
order of seconds (13). Together, these data indicate that human
αvβ3 interacts directly with P. falciparum TRAP.
The RGD Motif in TRAP Is Necessary, but Not Sufficient, for Binding
Integrin αvβ3. A well-characterized ligand binding determinant
for a subset of mammalian integrins, including αvβ3, is a three-
amino acid motif consisting of arginine-glycine-aspartic acid
(RGD) (19). P. falciparum TRAP contains an RGD sequence
between the TSR domain and the predicted transmembrane-
spanning region. To determine the importance of this se-
quence in integrin binding, we first added a cyclized peptide
containing an RGD motif, which is an inhibitor of RGD-
dependent αvβ3 interactions (20). Serial dilutions of the cyclo
(RGDfV) peptide showed a dose-dependent inhibition of the
interaction (Fig. 3A). To confirm the importance of this motif,
we used site-directed mutagenesis to mutate the RGD sequence
in TRAP to RGE, a conservative mutation known to disrupt
integrin ligand binding. We observed that the mutant RGE
TRAP was unable to bind human αvβ3 (Fig. 3B), confirming that
the RGD sequence was necessary for the interaction. The RGD
sequence is not a conserved feature of orthologous TRAP pro-
tein sequences from other Plasmodium species. To determine if
the interaction was conserved across species, the entire extra-
cellular domains of RGD-containing TRAP orthologs from a
gorilla parasite (Plasmodium praefalciparum) and a chimpanzee
parasite (Plasmodium reichenowi) and non RGD-containing
TRAP orthologs from two human parasites (Plasmodium vivax
and Plasmodium knowlesi) and a rodent parasite (Plasmodium
berghei) were expressed and tested for their ability to interact
with human integrin αvβ3. None of the TRAP orthologs that
lacked the RGD motif bound, confirming the importance of this
motif in binding αvβ3 (Fig. 3C). While P. praefalciparum bound
equivalently to P. falciparum, surprisingly, no binding of the
RGD-containing P. reichenowi TRAP was observed, suggesting
the requirement for additional integrin αvβ3 binding determi-
nants (Fig. 3C). Consistent with this, introducing an RGD motif
at an equivalent position in P. vivax TRAP did not result in a gain
of integrin αvβ3 binding activity (Fig. 3C). Together, these data
indicate that while the TRAP RGD motif is necessary, it is not
sufficient for the interaction with integrin αvβ3.
The VWA Domain of P. falciparum TRAP Is Required for Integrin αvβ3
Binding. To determine which other regions of TRAP are involved
in the interaction, we expressed discrete domains of the TRAP
ectodomain and tested them for αvβ3 binding. We could again
show that the RGD sequence was insufficient for binding, since a
protein containing the TSR domain and the RGD-containing
repeat region up to the transmembrane region did not interact
with αvβ3 (Fig. 4A). This also suggested that the TSR domain
was not involved in the interaction, and this was supported by the
fact that the TSR domain alone did not interact (Fig. 4A). These
data implied that the VWA domain might encode the additional
binding determinant, and although we were unable to express the
Fig. 3. The RGD sequence in TRAP is necessary, but not sufficient, for the
interaction with human αvβ3. (A) The TRAP–αvβ3 interaction can be inhibited
by addition of a cyclic RGD peptide mimetic. Dose-dependent inhibition of
the TRAP–αvβ3 interaction, but not the Cd200–Cd200R interaction, was ob-
served when prey proteins were preincubated with cyclo(Arg-Gly-Asp-D-
Phe-Val) peptide using the AVEXIS assay. (B) Mutating the RGD sequence
in P. falciparum TRAP to RGE abrogated binding to integrin αvβ3. TRAP
proteins were expressed as pentameric preys and tested for binding to
αvβ3 bait using the AVEXIS assay. The positive control (+ve) is the Cd200–
Cd200R interaction and the negative control (−ve) was Cd200 bait and
TRAP prey. (C ) The presence of an RGD motif in TRAP orthologs from other
Plasmodium species did not predict integrin αvβ3 binding. The entire
ectodomains of TRAP orthologs from the named Plasmodium species were
expressed as prey proteins and tested for their binding to integrin αvβ3 by
AVEXIS. The RGD-containing TRAP ortholog from P. reichenowi and mu-
tated RGD-containing P. vivax ortholog did not bind. The positive control
(+ve) is the Cd200–Cd200R interaction and the negative control (−ve) was
Cd200 bait and TRAP prey. Data points in A–C represent means ± SD, n = 3.
A representative experiment of at least two experiments is shown.
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VWA domain in isolation, a protein containing both VWA and
TSR domains but lacking the RGD sequence showed weak re-
sidual binding to αvβ3 (Fig. 4A). To examine the role of the
VWA domain in the context of the entire extracellular region, we
constructed a chimeric TRAP protein in which the VWA domain
from the nonbinding but RGD motif-containing P. reichenowi
TRAP was replaced with the VWA domain from P. falciparum
(Fig. 4B). This chimeric TRAP protein was able to interact with
αvβ3 in the AVEXIS assay (Fig. 4B), suggesting that the mini-
mum requirements for the αvβ3 interaction are the P. falciparum
TRAP VWA domain and RGD sequence. To investigate this
further, we mutated conserved residues in the MIDAS sequence
located within the VWA domain that are required for co-
ordinating divalent cations important for ligand binding. A
protein containing the double mutation S56A S58A displayed
much reduced binding to αvβ3 in the AVEXIS assay (Fig. 4C).
Consistent with this, titrating the divalent cation chelator EDTA
into a TRAP binding assay showed a dose-dependent inhibition
of binding (Fig. 4D). Together, these data suggest that TRAP
interacts with αvβ3 at two sites, with contributions from both the
VWA domain involving the MIDAS, and the RGD sequence.
HepG2 Cells Targeted for ITGAV Lose All TRAP Binding Activity. We
returned to cell-based assays to investigate the αvβ3–TRAP in-
teraction within the context of an intact cell. We observed that
the cell surface binding of TRAP was significantly increased in
the presence of manganese ions, which promote the formation of
proadhesive active integrin conformations (21), consistent with a
role for integrins in their active conformation in TRAP binding
(Fig. 5A). Preincubating cells with an inhibitory αvβ3 monoclonal
antibody whose epitope lies within the αv-subunit reduced TRAP
binding (Fig. 5B). Although this incomplete blocking is consis-
tent with TRAP using more than one contact site on αvβ3, it
could also indicate the presence of additional receptors on
HepG2 cells. To establish this, we again used CRISPR/Cas9
technology to genetically target the genes encoding both the
ITGAV and ITGB3 genes in HepG2 cells (SI Appendix, Fig. S2).
Strikingly, in ITGAV-targeted cells, all TRAP binding was lost,
demonstrating that the αv-subunit is the major determinant of
TRAP binding (Fig. 5C). Cells in which the ITGB3 gene had
been targeted, however, did not show any loss in cell surface
TRAP binding (Fig. 5C). Despite repeated attempts, the
HepG2 cell lines were refractory to single-cell cloning, so we
used a human erythroleukemia (HEL) cell line which we knew
could be made clonal and had high expression levels of both αv-
and β3-subunits. Similar to HepG2, all TRAP binding was lost in
ITGAV-targeted HEL cells, whereas targeting of ITGB3 had no
Fig. 4. The P. falciparum TRAP VWA domain is required for integrin αvβ3
binding. (A, Upper) A series of truncations of the P. falciparum TRAP extracellular
domain were expressed as pentameric preys. C-Term, C terminus; SP, signal
peptide; TM, transmembrane. (Lower) Binding with integrin αvβ3 quantified
by AVEXIS. The VWA domain alone was expressed at insufficient levels for
use in the assay. Only the full-length extracellular domain of TRAP was able
to fully interact with αvβ3 bait in AVEXIS; however, residual binding signal
was observed for the VWA + TSR construct. (B, Upper) Replacing the VWA
domain in the nonbinding P. reichenowi TRAP with the orthologous domain
from P. falciparum was sufficient to confer the ability to bind integrin αvβ3.
The entire extracellular regions of P. falciparum (Pf) and P. reichenowi (Pr) TRAP,
as well as a VWA-domain replacement chimera were expressed as prey proteins.
(Lower) Binding activity to integrin αvβ3 quantified by AVEXIS. (C) Mutating two
conserved serine residues within the MIDAS sequence of the P. falciparum TRAP
VWA domain significantly decreased binding to αvβ3. TRAP and the S56A S58A
TRAP were expressed as preys and used in the AVEXIS assay to test binding
against αvβ3 bait. In (A–C), the positive control (+ve) is the Cd200–Cd200R in-
teraction and the negative control (−ve) was Cd200 bait and TRAP prey. Bars
represent means ± SD, n = 3. A representative experiment of at least two in-
dependent experiments is shown. (D) The TRAP–αvβ3 interaction is divalent
cation dependent. Dose-dependent inhibition of the TRAP–αvβ3 interaction, but
not the Cd200-Cd200R interaction, was observed using the AVEXIS assay when
prey proteins were preincubated with increasing concentrations of divalent cat-
ion chelator EDTA. Data points represent mean ± SD, n = 3. A representative
experiment of at least three independent experiments is shown.
Fig. 5. The integrin αv-subunit is essential for TRAP binding to HepG2 cells.
(A) Binding of an oligomerized TRAP binding probe to HepG2 cells is en-
hanced by addition of 2 mM MnCl2 to the buffer. (B) Binding of TRAP to
HepG2 cells can be partially blocked by preincubation with an anti-αv anti-
body (mouse IgG1 clone 272-17E6), but not an isotype-matched monoclonal
antibody to another surface protein (anti-BSG mouse IgG1 clone MEM-
M6/6). (C) Binding of TRAP is completely abolished in HepG2 and HEL cells in
which ITGAV, but not ITGB3, genes have been targeted using CRISPR/
Cas9 technology. Negative (−ve) controls in A–C are Cd200 oligomerized
around streptavidin–phycoerythrin, which does not stain cell surfaces.
(D) TRAP is able to bind integrins αvβ5 and αvβ6, in addition to αvβ3. Seven
RGD-binding integrins were expressed as biotinylated bait proteins and
screened by AVEXIS for interaction against TRAP prey. Positive control (+ve)
is the Cd200–Cd200R interaction and the negative control (−ve) was
Cd200 bait and TRAP prey. Bars represent mean ± SD, n = 3. A representative
experiment of at least three independent experiments is shown.
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effect on TRAP binding (Fig. 5C). The αv-subunit is a pro-
miscuous integrin α-subunit known to form functional integrins
with four other β-subunits, and the retention of TRAP binding
following ablation of the ITGB3 gene could reveal redundancies
with other αv-subunit–containing integrins. To investigate this,
we expressed all five αv-subunit–containing integrins, as well as
two other RGD-binding integrins (α5β1 and α8β1), and tested
their ability to bind TRAP. We observed that integrins αvβ5 and
αvβ6 were also able to bind TRAP, albeit with a lower relative
activity compared with integrin αvβ3, while the other RGD-
binding integrins showed no TRAP binding activity (Fig. 5D).
Together, these data demonstrate a critical role for the integrin
αv-subunit in TRAP binding at cell surfaces.
The TRAP–Integrin Interaction Has No Major Role in Hepatocyte
Invasion, but May Be Involved in Dermal Migration. To investigate
the functional role of the TRAP–integrin interaction, we first
used in vitro P. falciparum sporozoite invasion assays of HepG2
cells. Unlike the parental HepG2 cell line, we observed that our
ITGAV-targeted HepG2 cells grew in small clusters that adhered
poorly to tissue culture plastic; however, precoating the substrate
with collagen improved cellular adherence to a degree that
sporozoite invasion experiments could be attempted. No signif-
icant difference in the ability of P. falciparum sporozoites to
invade ITGAV-targeted compared with parental HepG2 cells
was observed (Fig. 6A), although we did not consider this con-
clusive due to the altered adhesive properties of the cells. To
circumvent these difficulties, we added anti-αv antibodies (Fig.
6B) and soluble integrin ectodomains (Fig. 6C) to P. falciparum
sporozoite invasion assays and, again, observed no strong effect,
suggesting that this interaction has no major role in sporozoite
invasion of hepatocytes. Sporozoites interact with many different
tissues before invading hepatocytes. Because we observed that
P. falciparum TRAP was able to interact with the mouse αvβ3
ortholog (SI Appendix, Fig. S3A), we genetically replaced P. berghei
TRAP with either the P. falciparum ortholog or a nonbinding
RGE mutant. Although many functions of P. berghei TRAP were
complemented, we repeatedly observed that the transgenic par-
asites did not glide or develop in a hepatocyte cell line compared
with control parental P. berghei parasites, suggesting that some
aspects of TRAP function were not fully complemented, pre-
cluding confident interpretations of the role of the interaction
using this approach (SI Appendix, Fig. S3). To investigate the
requirement of the interaction in the host, we next infected Itgb3-
deficient mice with fluorescent transgenic P. falciparum parasites
and tracked their motility and behavior in the dermis using in-
travital microscopy (22). We observed that P. falciparum sporo-
zoites glide with greater speed (Fig. 6D) and displace over larger
distances from the inoculation site in Itgb3-deficient mice com-
pared with wild-type siblings (Fig. 6E). Together, these data
suggest that the TRAP–integrin interaction has no major role in
P. falciparum hepatocyte invasion but influences the behavior of
sporozoites in the dermis.
Discussion
In contrast to the detailed descriptions of how sporozoites interact
with host cells, remarkably little is known about the molecular in-
teractions involved. Both circumsporozoite protein (CSP) and TRAP
have been demonstrated to interact with highly sulfated proteogly-
cans displayed on tissues in the liver sinusoids, which may provide a
molecular explanation for sporozoite homing to this organ (23, 24).
Other cell surface molecules that have roles in the liver stage of in-
fection include CD81, SR-B1, CD68, and EphA2, but the details of
how they interact with the parasite are unclear (2). Our discovery that
TRAP is able to interact with human αv-subunit–containing integrins
provides an important precedent demonstrating that sporozoite
surface proteins do interact with host cell surface receptor proteins.
Here, we have shown a critical requirement for the integrin
αv-subunit in TRAP binding at cell surfaces, but because this
integrin α-subunit is expressed in most tissues, the expression
pattern of the β-subunit partners may determine cellular binding
selectivity. Our experiments suggest redundancy in β-subunit
usage, with αvβ3 exhibiting preferential binding compared with
αvβ5 and αvβ6 integrins. Both β5 and β6 are broadly distributed,
whereas β3 is restricted, with the αvβ3 integrin expressed highly
on osteoclasts but also on endothelial cells, vascular smooth
muscle, and platelets (25). Although these integrins are broadly
expressed, we have shown that TRAP binding is promoted in the
presence of manganese ions that are proadhesive integrin “ac-
tivators,” suggesting that TRAP preferentially binds integrins in
their activated ligand binding conformation. A preference for
binding integrins in their active conformation would restrict the
number of receptors available and may serve to localize the
TRAP–integrin interactions to clusters of integrins in their ac-
tivated state, as has been suggested for focal adhesions (26). The
sporozoite may exploit these binding preferences as a signal to
switch between gliding and cell traversal or invasion behaviors.
Using in vitro HepG2 sporozoite invasion assays, however, we
did not observe any major effect when perturbing the interaction
Fig. 6. The TRAP–integrin interaction has no major role in hepatocyte in-
vasion but may be involved in sporozoite dermal migration. The effect of
perturbing the TRAP–integrin interaction on the ability of P. falciparum
sporozoites to invade HepG2 cells in vitro was assessed by comparing ITGAV-
targeted cells relative to parental HepG2-Cas9 controls (A); by allowing
sporozoites to invade in the continued presence of the anti-αv monoclonal
antibody (100 μg/mL) or an isotype-matched control antibody (100 μg/mL)
(B); or by comparing 200 nM TRAP binding soluble recombinant integrin
ectodomain αvβ3 relative to nonbinding control α8β1 (C). Bars represent
mean ± SD, n = 2. (D) Itgb3−/− C57BL/6 mice and wild-type (WT) siblings were
infected with fluorescent P. falciparum sporozoites by intradermal injection
into the ear pinna, and their circular motility was observed by intravital video
microscopy at 5 min (Itgb3−/−, 260 tracks, n = 3; WT, 316 tracks, n = 3) and
10 min (Itgb3−/−, 297 tracks, n = 5; WT, 338 tracks, n = 5). Speed data are
represented as box and whisker plots, with the horizontal line representing
the mean and the whiskers representing the 10th to 90th percentiles; outliers
are plotted individually. (E) Displacement of P. falciparum sporozoites 5 and
10 min after injection, represented as box and whisker plots, with the hori-
zontal line representing the mean and the whiskers representing the 10th to
90th percentiles. ****P ≤ 0.0001 Kruskal–Wallis test. p.i., postinjection.
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using antibodies, recombinant proteins, or cells lacking the
integrin αv-subunit. To investigate the possibility that the in-
teraction may occur at a different stage of the sporozoite journey
from the dermis to the hepatocytes, we used intravital micros-
copy to quantify sporozoite behavior in the dermis of transgenic
mice. Itgav-deficient mice are embryonic lethal (27), and al-
though functional redundancies within integrin β-chain are a
possibility, we observed that sporozoites were able to move faster
within the dermis of Itgb3-deficient mice, suggesting that the
interaction could impede the movement of the parasites. This
would suggest that TRAP does not use integrin binding as a
gliding substrate, but rather as a stop or brake to alter its gliding
behavior in response to a localized cellular signal in the host. The
VWA domain in TRAP is structurally homologous to the I-
domain of integrins, and structural studies have shown that
both TRAP VWA and the integrin I-domain contain metal ion-
dependent adhesion sites whose affinity for ligand can be regu-
lated through conformational changes and thereby regulate
integrin adhesiveness and, potentially, the extension of the
TRAP ectodomain (11, 28). Analysis of the cocrystal structure of
the RGD-containing pro-TGF-β1 ligand with the αvβ6 integrin
has revealed that upon ligand binding, integrins can apply force
to and thereby reshape their ligands (29). Pro-TGF-β1 binds its
integrin receptor with a high affinity (KD of ∼50 nM) (30),
similar to the affinity of TRAP for its integrin receptor (KD of
∼10 nM). One possibility is that the high affinity of TRAP
binding and conformational changes in the integrin results in the
application of force through TRAP, which influences parasite
motility by locking the extracellular regions of TRAP into its
extended conformation.
Since the demonstration over 20 y ago that TRAP is essential
for parasite motility, it has been a focus for malaria vaccines
targeting the preerythrocytic stage of Plasmodium infections. By
identifying αv-subunit–containing integrins as a host receptor for
TRAP, we have addressed one of the main outstanding questions
relating to the function of TRAP and provide an important
example that sporozoite ligands can directly interact with
host receptors.
Materials and Methods
Full details are available in SI Appendix, SI Materials and Methods.
Recombinant Protein Expression and Protein Interaction Assays. Proteins were
expressed in HEK293 cells and AVEXIS assays were performed as previously
described (15). In binding assays requiring EDTA or cyclo(RGDfV), serial di-
lutions were preincubated with the prey proteins before addition to the
baits. Avid integrin preys were made by clustering biotinylated integrin
heterodimers around a streptavidin-alkaline phosphatase conjugate. Cell
binding was performed by clustering biotinylated proteins around a fluo-
rescent streptavidin conjugate before presenting to cells and analysis by
flow cytometry.
Gene Targeting Using CRISPR/Cas9. Gene-specific guide RNAs were delivered
to Cas9-expressing cell lines by lentiviral transduction after cloning guide
RNAs into the pKLV2-U6gRNA-PGKpuro2ABFP-W expression vector. Gene-
targeted cells were selected using puromycin and were cultured for at least
8 d before use.
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